Answers are grounded in this paper and cite their sources.
DISCOVERY OF THE Philadelphia chro-mosome (Ph1) in cases of chronic myelocytic leukemia (1) provided the first demonstration of a specific chromosomal abnormality in a human neoplasm. How-ever, this abnormal cytogenetic feature is not present in all cases of this disorder, and a small number of patients said to be typical otherwise, but lacking the Ph1 chromosome, have been described (2). Since 1961, cytogenetic studies have formed part of the initial and subsequent hematologic investigation of patients with chronic mye-locytic leukemia seen at this Institute. During this time, we have observed and treated both Ph1+ and Ph1- patients. The contrasts between the two groups have been striking. Clinically, hematologically, and in therapeutic response, the Ph1- pa-tients appear to differ from the Ph1+ group. CLINICAL MATERIAL AND METHODS This report is based on clinical and cyto-genetic studies of 28 patients with chronic myelocytic leukemia (CML) referred to this Institute from 1959 to 1963. The group comprises 18 males and 10 females, ranging in age from 33 to 79 years. Detailed descrip-tions of the karyotypes of 16 of these pa-tients have been reported previously (3). Bone marrow aspirations were performed as part of our initial study and at periodic intervals thereafter. Blood and marrow were processed for chromosome analysis by techniques previously described (3). When splenic aspiration was performed, the aspi-rate was processed in the same manner as bone marrow smears. White blood cell counts were performed using an electronic cell counter (Coulter Instruments). Hemo-globin was determined using the cyan-methemoglobin method, and platelets were counted by a technique employing phase microscopy. Leukocytic alkaline phospha-tase activity was estimated by the method
No takes yet. Share an insight, caveat, or question.
Stephen Krauss (1964) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: